Clinical trial • Phase I • Oncology

XL092 for Clear cell renal cell carcinoma | Non-clear cell renal cell carcinoma | Hormone receptor-positive breast cancer | Metastatic castration-resistant prostate cancer | Colorectal cancer

Phase I trial of XL092 for Clear cell renal cell carcinoma | Non-clear cell renal cell carcinoma | Hormone receptor-positive breast cancer | Metastatic ca…

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Clear cell renal cell carcinoma | Non-clear cell renal cell carcinoma | Hormone receptor-positive breast cancer | Metastatic castration-resistant prostate cancer | Colorectal cancer
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
09-08-2024
First CTIS Authorization Date
11-09-2024

Trial design

None/Not specified-controlled, adaptive Phase I trial across 24 sites in Belgium, Czechia, Germany and others.

Comparator
None/Not specified
Adaptive
True - Dose-escalation and expansion design; specific escalation rules not provided in the public record.
Single Multiple Or Escalation Dose Combined
Yes
Target Sample Size
180

Recruitment

Planned Sample Size
180
Recruitment Window Months
94

Geography

Total Number Of Sites
24
Total Number Of Participants
140

Belgium

Earliest CTIS Part Ii Submission Date
30-08-2024
Latest Decision Or Authorization Date
12-09-2024
Processing Time Days
13
Number Of Sites
3
Number Of Participants
6

Sites

Site Name
Antwerp University Hospital
Department Name
Medical Oncology
Principal Investigator Name
Hans Prenen
Principal Investigator Email
hans.prenen@uza.be
Contact Person Name
Hans Prenen
Contact Person Email
hans.prenen@uza.be
Site Name
Cliniques Universitaires Saint-Luc
Department Name
Medical Oncology
Principal Investigator Name
Jean-Pascal Machiels
Principal Investigator Email
jean-pascal.machiels@uclouvain.be
Contact Person Name
Jean-Pascal Machiels
Site Name
Universitair Ziekenhuis Gent
Department Name
Medical Oncology
Principal Investigator Name
Sylvie Rottey
Principal Investigator Email
sylvie.rottey@uzgent.be
Contact Person Name
Sylvie Rottey
Contact Person Email
sylvie.rottey@uzgent.be

Czechia

Earliest CTIS Part Ii Submission Date
30-08-2024
Latest Decision Or Authorization Date
10-03-2026
Processing Time Days
557
Number Of Sites
1
Number Of Participants
4

Sites

Site Name
Fakultni Thomayerova nemocnice
Department Name
Oncology
Principal Investigator Name
Tomas Buchler
Principal Investigator Email
tomas.buchler@ftn.cz
Contact Person Name
Tomas Buchler
Contact Person Email
tomas.buchler@ftn.cz

Germany

Earliest CTIS Part Ii Submission Date
30-08-2024
Latest Decision Or Authorization Date
11-03-2026
Processing Time Days
558
Number Of Sites
2
Number Of Participants
10

Sites

Site Name
Klinikum rechts der Isar der TU Muenchen AöR
Department Name
Urological Oncology
Principal Investigator Name
Margitta Retz
Principal Investigator Email
margitta.retz@tum.de
Contact Person Name
Margitta Retz
Contact Person Email
margitta.retz@tum.de
Site Name
Haematologisch Onkologische Praxis Eppendorf
Department Name
Oncology
Principal Investigator Name
Alexander Stein
Principal Investigator Email
stein@hope-hamburg.de
Contact Person Name
Alexander Stein
Contact Person Email
stein@hope-hamburg.de

France

Earliest CTIS Part Ii Submission Date
30-08-2024
Latest Decision Or Authorization Date
11-03-2026
Processing Time Days
558
Number Of Sites
9
Number Of Participants
57

Sites

Site Name
Hospices Civils De Lyon
Department Name
Medical Oncology
Principal Investigator Name
Benoit You
Principal Investigator Email
benoit.you@chu-lyon.fr
Contact Person Name
Benoit You
Contact Person Email
benoit.you@chu-lyon.fr
Site Name
Institut Paoli Calmettes
Department Name
Medical Oncology
Principal Investigator Name
Gwenaelle Gravis-Mescam
Principal Investigator Email
gravisg@ipc.unicancer.fr
Contact Person Name
Gwenaelle Gravis-Mescam
Contact Person Email
gravisg@ipc.unicancer.fr
Site Name
Institut Bergonie
Department Name
Medical Oncology
Principal Investigator Name
Guilhem Roubaud
Principal Investigator Email
g.roubaud@bordeaux.unicancer.fr
Contact Person Name
Guilhem Roubaud
Site Name
Centre Jean Perrin
Department Name
Medical Oncology
Principal Investigator Name
Hakim Mahammedi
Principal Investigator Email
hakim.mahammedi@cjp.fr
Contact Person Name
Hakim Mahammedi
Contact Person Email
hakim.mahammedi@cjp.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Medical Oncology
Principal Investigator Name
Jacques Medioni
Principal Investigator Email
jacques.medioni@aphp.fr
Contact Person Name
Jacques Medioni
Contact Person Email
jacques.medioni@aphp.fr
Site Name
Centre Francois Baclesse
Department Name
Medical Oncology
Principal Investigator Name
Florence Joly
Principal Investigator Email
f.joly@baclesse.unicancer.fr
Contact Person Name
Florence Joly
Contact Person Email
f.joly@baclesse.unicancer.fr
Site Name
Centre Hospitalier Universitaire De Poitiers
Department Name
Medical Oncology
Principal Investigator Name
Nicolas Isambert
Principal Investigator Email
nicolas.isambert@chu-poitiers.fr
Contact Person Name
Nicolas Isambert
Site Name
Institut De Cancerologie De L Ouest
Department Name
Medical Oncology
Principal Investigator Name
Marie Robert
Principal Investigator Email
marie.robert@ico.unicancer.fr
Contact Person Name
Marie Robert
Contact Person Email
marie.robert@ico.unicancer.fr
Site Name
Oncopole Claudius Regaud
Department Name
Medical Oncology
Principal Investigator Name
Damien Pouessel
Principal Investigator Email
pouessel.damien@iuct-oncopole.fr
Contact Person Name
Damien Pouessel

Spain

Earliest CTIS Part Ii Submission Date
30-08-2024
Latest Decision Or Authorization Date
17-03-2026
Processing Time Days
564
Number Of Sites
9
Number Of Participants
63

Sites

Site Name
Hospital Del Mar
Department Name
Medical Oncology
Principal Investigator Name
Alejo Martín Rodríguez-Vida Rodríguez
Principal Investigator Email
arodriguezvida@psmar.cat
Contact Person Name
Alejo Martín Rodríguez-Vida Rodríguez
Contact Person Email
arodriguezvida@psmar.cat
Site Name
Hospital Clinico San Carlos
Department Name
Medical Oncology
Principal Investigator Name
Jorge Bartolomé Arcilla
Principal Investigator Email
jorge.bartolome@salud.madrid.org
Contact Person Name
Jorge Bartolomé Arcilla
Site Name
Hospital Clinic De Barcelona
Department Name
Medical Oncology
Principal Investigator Name
Begoña Mellado González
Principal Investigator Email
bmellado@clinic.cat
Contact Person Name
Begoña Mellado González
Contact Person Email
bmellado@clinic.cat
Site Name
Hospital Quironsalud Barcelona
Department Name
Medical Oncology
Principal Investigator Name
Fabricio Racca Bussano
Principal Investigator Email
fabricio.racca@iob-onco.com
Contact Person Name
Fabricio Racca Bussano
Contact Person Email
fabricio.racca@iob-onco.com
Site Name
Hospital Universitari Vall D Hebron
Department Name
Medical Oncology
Principal Investigator Name
Cristina Suárez Rodríguez
Principal Investigator Email
csuarez@vhio.net
Contact Person Name
Cristina Suárez Rodríguez
Contact Person Email
csuarez@vhio.net
Site Name
University Hospital Virgen Del Rocio S.L.
Department Name
Medical Oncology
Principal Investigator Name
Alejandro Falcon Gonzalez
Principal Investigator Email
alejandro.falcon.sspa@juntadeandalucia.es
Contact Person Name
Alejandro Falcon Gonzalez
Site Name
Hospital Universitario 12 De Octubre
Department Name
Medical Oncology
Principal Investigator Name
Guillermo De Velasco Oria de Rueda
Principal Investigator Email
guillermoantonio.velasco@salud.madrid.org
Contact Person Name
Guillermo De Velasco Oria de Rueda
Site Name
Parc Tauli Hospital Universitari
Department Name
Medical Oncology
Principal Investigator Name
Enrique Gallardo Díaz
Principal Investigator Email
egallardo@tauli.cat
Contact Person Name
Enrique Gallardo Díaz
Contact Person Email
egallardo@tauli.cat
Site Name
Hospital General Universitario Gregorio Maranon
Department Name
Medical Oncology
Principal Investigator Name
Aitana Calvo Ferrandiz
Principal Investigator Email
pilaraitana.calvo@salud.madrid.org
Contact Person Name
Aitana Calvo Ferrandiz

Sponsor

Primary sponsor

Full Name
Exelixis Inc.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Investigational products

Investigational Product Name
XL092
Combination Treatment
Yes

Related trials

Other published trials that may interest you.